BPC-157 + KPV blend

BPC-157 is stable in gastric juice, which is the reason oral dosing is taken seriously for it rather than dismissed, and it drives angiogenesis and mucosal repair through VEGFR2 and nitric oxide signalling while protecting against NSAID and alcohol-induced damage in rodent models. KPV is the C-terminal tripeptide of alpha-MSH and blocks NF-kappaB nuclear translocation, cutting the inflammatory signalling that keeps a damaged mucosa damaged; it is absorbed intact through the PepT1 transporter expressed on intestinal epithelium, so an oral dose reaches the tissue you are aiming at. The two are complementary in a way most blends are not - one repairs, the other stops the process driving the injury - and unusually for this class both components have a genuine rationale for the same route. That makes this the one blend where the oral capsule form is not a compromise.

Targets: NF-kappaB nuclear translocation, PepT1 intestinal peptide transporter, VEGFR2 and nitric oxide signalling, Intestinal tight junction integrity, Mast cell stabilisation

• · 1,000 to 2,000 mcg of total blend from a one-to-one vial is 500 to 1,000 mcg of each component, which sits inside the standalone oral band for both. Reconstituted solution is simply swallowed, or a delayed-release capsule is used to get past the stomach and reach the colon.
• · 250 to 500 mcg of each component per dose. Used when the target is systemic inflammation or skin rather than the gut lining itself. For a purely luminal gut problem the oral route makes more sense and costs less.

Work out your exact syringe units →

• commonLoose stools or transient gut upset in the first week— Usually settles. Most commonly reported when starting the oral form.
• commonInjection-site redness with the subcutaneous form— Resolves in a day. Rotate sites.
• uncommonNausea— More likely if taken with food rather than on an empty stomach.
• uncommonTransient flushing or itch— Sometimes attributed to the KPV arm acting on mast cells.
• rareUnwanted tissue growth from sustained pro-angiogenic signalling— Theoretical rather than documented, but the reason indefinite use is a bad idea and active malignancy is a contraindication.

• Active or recent malignancy - BPC-157 is pro-angiogenic and gastrointestinal cancers are exactly the tissue you would be dosing.
• Pregnancy and breastfeeding.
• Undiagnosed gastrointestinal bleeding or unexplained weight loss - investigate before masking symptoms.
• Drug-tested athletes - BPC-157 is WADA-prohibited.

• redundantbpc-157 — Half the vial. Adding a standalone BPC-157 protocol on top is double-dosing.
• redundantkpv — The other half. If you need more KPV than the blend delivers, buy KPV separately rather than raising the whole dose.
• redundantklow — KLOW already contains both BPC-157 and KPV, plus a large copper load. Running both duplicates the two components you are actually after.
• redundantbpc-157-arginate — The same peptide as a more stable salt. Running both is one compound counted twice.
• cautionNSAIDs — The rodent evidence that BPC-157 protects against NSAID gut damage is one of its stronger findings, but it is not a licence to keep taking NSAIDs through a mucosal injury you are trying to heal.
• cautionBiologic or immunosuppressive IBD therapy — No interaction data exists. The real risk is behavioural - people reduce or stop proven therapy because the peptides seem to be helping, and relapse.

• · Check whether the product states per-component amounts; many oral capsule versions do not, and a total-only label makes dosing guesswork.
• · Track the actual symptom with a simple daily score rather than general impression, since gut symptoms fluctuate on their own.
• · For diagnosed inflammatory bowel disease, keep faecal calprotectin or whatever objective marker your clinician uses in the loop - symptom improvement without marker improvement is not remission.
• · Do not stop or reduce prescribed therapy on the strength of feeling better on a peptide blend.

Neither component is approved for human use in the US or EU and both are sold as research chemicals. In April 2026 the FDA removed BPC-157 and KPV from the Category 2 bulk drug substances list, and on 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8-6 to recommend both for the 503A Bulks List; the FDA has not acted on that non-binding recommendation. Oral capsule products sold as supplements are mislabelled - neither peptide is a lawful dietary ingredient.

• Dalmasso et al., PepT1-mediated tripeptide KPV uptake and attenuation of experimental colitis (preclinical)
• Sikiric et al., BPC 157 and gastrointestinal cytoprotection, including NSAID and alcohol lesion models (review)
• Kannengiesser et al., melanocortin-derived tripeptide KPV in intestinal inflammation (preclinical)
• Vendor labels for BPC-157 / KPV blend vials and delayed-release oral capsules (other)

This is the most mechanistically coherent blend in the class, and the reason is that both components have a genuine argument for the same route to the same tissue - which is not true of any other product on this page. KPV's action is intracellular and transporter-dependent. Dalmasso's 2008 Gastroenterology work established that nanomolar KPV inhibits NF-kappaB activation in intestinal epithelial and immune cells, that it enters those cells through PepT1, and that the effect does not require melanocortin receptors. PepT1 is minimally expressed in healthy colon and is upregulated in inflamed colonic epithelium. That gives you a self-targeting mechanism: the sicker the tissue, the more drug it takes up. Downstream of NF-kappaB blockade you get reduced transcription of TNF-alpha, IL-6, IL-1beta and IL-8, and reduced neutrophil recruitment. Kannengiesser's independent murine IBD work the same year reached compatible conclusions, and the later Merlin-group work on hyaluronic-acid-functionalised oral nanoparticles shows where serious KPV research went - toward getting more of it into the colon, not toward injecting it. BPC-157 supplies the repair half. Its gastrointestinal literature is the oldest and largest part of its evidence base, covering NSAID-induced lesions, alcohol-induced lesions, fistula healing and anastomotic healing in rodents. Mechanistically it works through VEGFR2 expression and the VEGFR2-Akt-eNOS axis, driving angiogenesis and perfusion into damaged mucosa, plus reported effects on tight junction integrity. It still has no identified receptor, and that gap applies here as everywhere. The complementarity is real and specific. Chronic mucosal injury is a loop: damage drives NF-kappaB-mediated inflammatory signalling, which drives more damage and impairs repair. KPV interrupts the signalling arm; BPC-157 accelerates the repair arm. Blocking inflammation without repairing tissue leaves you dependent on the blocker, and repairing tissue while inflammatory signalling continues means repairing into a headwind. Addressing both is what a decent gut protocol would look like if someone designed one deliberately. Coherent is not demonstrated. Nobody has tested this combination in any species. The KPV colitis data is mice, the BPC-157 gut data is rodents, and the human experience is entirely anecdotal. One asymmetry worth naming: the two mechanisms have different timescales. NF-kappaB blockade is fast and produces symptom relief within one to two weeks, and it stops when you stop. Mucosal repair is slow, takes six to twelve weeks, and persists. That difference is exactly why symptom improvement on this blend is a poor guide to whether the lining has healed, and why faecal calprotectin is the marker that matters.

The first failure is the oral capsule label. Many oral products state only a total milligram figure with no per-component breakdown, which means you genuinely do not know how much KPV or BPC-157 you are taking, and any dose calculation is a guess. This is more common with capsules than with vials because capsule products are sold into a supplement-shaped market with supplement-shaped labelling. If there is no per-component amount, treat the dose as unknown. The second is treating symptom relief as healing. The KPV arm is a fast-acting signalling brake and it will make you feel better within two weeks whether or not the mucosa is repairing. Repair takes six to twelve weeks and you cannot feel it. This is not a subtle distinction - it is the difference between a blend that is helping and a blend that is hiding something, and calprotectin is the only way to tell. The third is stopping working treatment, which is the failure mode that hospitalises people. It is listed twice on this page deliberately. The fourth is using it on undiagnosed symptoms. Unexplained bleeding, unexplained weight loss or a persistent change in bowel habit needs investigation first. An anti-inflammatory peptide blend is exceptionally good at making a delayed diagnosis feel reasonable at the time, and BPC-157 is pro-angiogenic in the exact tissue where a delayed diagnosis matters most. The fifth is expecting the injectable version to do what the oral evidence describes. Injecting KPV bypasses PepT1 entirely and delivers it systemically instead of to the gut lining. That is a different and much less characterised proposition, and if your target is the lining you should be swallowing it. The sixth is running it for months because the underlying condition is chronic. Four to eight weeks then a break is the convention, and the reason is not copper as it is in KLOW but simply that neither peptide has human safety data past that horizon and one of them drives angiogenesis. People with IBD commonly run these for months and there is no evidence base for that practice in either direction. The seventh is the salt question. BPC-157 arginate is meaningfully more stable in solution than the acetate, which matters for a reconstituted vial sitting in a fridge for a month. Most labels do not say which you have. The eighth is dosing with food. Both components are better taken on an empty stomach, and nausea is more likely when they are not.

1. 1 mgWeek 1 — 1,000 mcg of total blend once daily on an empty stomach - 500 mcg each of BPC-157 and KPV from a one-to-one product. Transient loose stools in the first few days are common when starting oral BPC-157 and usually settle within a week, so start at the low end and let that pass before judging anything.
2. 2 mgWeeks 2 to 4 — 2,000 mcg of total blend daily, usually split as 1,000 mcg on waking and 1,000 mcg before bed, both on an empty stomach. Given BPC-157's sub-30-minute half-life, splitting the dose is more defensible than a single daily one. This is the working protocol.
3. 2 mgWeeks 4 to 8 — Hold and reassess with objective measurement rather than impression. The KPV arm should have moved symptoms inside two weeks. If nothing has changed by week four, raising the dose is unlikely to help and this is not your answer.
4. —Week 8 to 12 — Stop and take a break at least as long as the run, and recheck calprotectin before deciding whether to repeat. Nothing in this blend forces a short cycle the way copper does in the GLOW family - the limit is simply that neither peptide has human safety data past that horizon and BPC-157's pro-angiogenic mechanism is not one to leave running indefinitely.

• PepT1 (SLC15A1) intestinal peptide transporter

  KPV's route into intestinal epithelial and immune cells. Upregulated in inflamed colon, so uptake self-targets to diseased tissue. This transporter is the reason the oral route for this blend is the evidence-based one rather than a compromise.

• NF-kappaB signalling

  Inhibited by KPV at nanomolar concentrations after PepT1-mediated uptake. Reduces transcription of TNF-alpha, IL-6, IL-1beta and IL-8 and reduces neutrophil recruitment into the mucosa. Fast-acting, and it stops when you stop.

• VEGFR2 and the Akt-eNOS axis

  The BPC-157 arm. Angiogenesis and improved perfusion into damaged mucosa, which is the plausible basis for the ulcer, fistula and anastomotic healing findings in rodents. No demonstrated direct binding.

• Intestinal tight junction proteins

  BPC-157 is reported to improve barrier integrity, which is the mechanistic claim behind its use for intestinal permeability. Rodent data, and the human relevance of the permeability construct itself is contested.

• Melanocortin receptors

  Historically assumed to mediate alpha-MSH fragment effects, but Dalmasso showed KPV's intestinal anti-inflammatory action is melanocortin-receptor-independent. This matters practically - it means KPV should not cause the pigmentation effects of full melanocortin agonists.

• Mast cells

  Reported stabilisation inherited from the alpha-MSH literature, the basis for using this pairing in histamine-flavoured gut presentations. The least well-supported claim in this record.

Days 1 to 7: transient loose stools or mild gut upset are common when starting the oral form and usually settle within a week. Confusing, because that is also the symptom many people are treating - expect it, and do not abandon the protocol in the first few days because of it. Weeks 1 to 2: this is when the KPV arm shows itself if it is going to. Reflux, urgency, bloating and cramping are the fastest responders, consistent with NF-kappaB blockade rather than tissue repair. Skin manifestations, if you have them, often move on the same timeline. Weeks 2 to 4: symptomatic improvement consolidates. This is also the honest go or no-go point. If nothing has changed by week four, the blend is not working for you and continuing is optimism rather than a plan. Weeks 6 to 12: mucosal repair, if it is happening, is in this window. You cannot feel it and you should not try - this is a calprotectin question. The BPC-157 arm's contribution is here, and it is slower and quieter than the KPV arm's. After stopping: the anti-inflammatory effect fades within days to a couple of weeks because you removed a signalling brake rather than fixed a driver. That fade is expected and is not evidence of dependence or rebound in any pharmacological sense. Whatever mucosal repair occurred persists, because it is tissue rather than a drug effect. If symptoms return immediately and completely on stopping, the honest reading is that the blend was suppressing rather than healing, and the underlying problem still needs addressing.

The single most important note is about what not to stop. Anyone with diagnosed inflammatory bowel disease on mesalazine, a thiopurine or a biologic should treat this blend as an adjunct and nothing else. There is no interaction data in either direction and the real hazard is behavioural: the KPV arm suppresses inflammatory signalling fast, symptoms improve inside two weeks, people taper their proven therapy, and they relapse. Symptom relief is not remission. Keep calprotectin in the loop and do not touch prescribed treatment on the strength of feeling better. Route is the main stacking decision. For a luminal gut problem, oral is the mechanistically correct choice for both components - BPC-157 is gastric-acid stable and KPV needs intestinal PepT1. A delayed-release capsule that gets past the stomach is a genuine advantage rather than a marketing feature. The subcutaneous version makes sense only if your target is systemic inflammation or skin rather than the lining itself, and it is the more expensive way to do it. Glutamine at 5 to 10 g, zinc carnosine and a period of reduced fermentable carbohydrate are the boring adjuncts with more human data behind them than anything in this vial. None conflicts. NSAIDs are the interaction people cite most. BPC-157's protection against NSAID-induced gut lesions is genuinely one of its most reproducible rodent findings and part of why it is bought. It is not a licence to keep taking NSAIDs through a mucosal injury you are trying to heal - protection in a rat model of acute lesion formation is not the same as safety during chronic use in a damaged human gut. Proton pump inhibitors do not conflict, but they change the environment the oral form encounters. Whether raising gastric pH affects a peptide selected for acid stability is unknown and probably minor. Probiotics have no interaction data. If you start one at the same time as this blend you will not know which did anything, and gut symptoms fluctuate enough on their own that attribution is already hard. Do not stack with KLOW, which contains both of these plus a copper load and a cycle cap you have no gut-related reason to accept. Do not stack with standalone BPC-157 or BPC-157 arginate, which is the same compound as a different salt.

Against KLOW: KLOW contains both of these plus GHK-Cu and TB-500, and the copper caps your cycle at four weeks for reasons that have nothing to do with your gut. For a gut problem this two-peptide blend is the better-designed product - same active components, no copper ceiling, available orally, cheaper. Against standalone BPC-157: for a purely structural mucosal problem with no strong inflammatory component, standalone BPC-157 is cheaper and does most of the work. KPV earns its place when inflammation is the driver rather than the consequence, which is most of the time in IBD-shaped presentations but not in, say, a simple NSAID-induced erosion. Against standalone KPV: cheaper, dose-flexible, unremarkable safety profile, and runnable for months. If your problem is purely inflammatory and you are not trying to heal a defect, standalone KPV is a reasonable and less expensive choice. Against the injectable version of this same blend: for a luminal problem the oral form is mechanistically better and cheaper. The subcutaneous version is the right choice only if you want systemic or dermatological effects. Against actual IBD treatment: this is not a competitor to mesalazine, a thiopurine, or an anti-TNF or anti-integrin biologic, and no comparison has ever been run. Those drugs have decades of controlled data, defined remission endpoints and known risks. This blend has mouse data and a coherent story. Used alongside proper treatment it is a reasonable thing to try; used instead of it, the failure mode is severe and well documented in the gastroenterology literature - just not with these particular compounds. Against dietary and lifestyle intervention: exclusive enteral nutrition, specific exclusion diets and smoking cessation in Crohn's all have more human evidence than this blend. They are also harder, which is why peptides get bought first.

$45–$120/month. A 10 mg plus 10 mg vial at 2,000 mcg of total blend daily lasts about ten days, so roughly three vials a month at the working dose - though oral protocols vary widely and many people run less. Delayed-release capsule products generally cost more per milligram than vials but remove reconstitution and give the KPV arm the colon-targeted delivery its evidence is built on, which is a defensible premium. Budget separately for baseline and follow-up calprotectin, which is the single most useful expenditure attached to this product. Observed market ranges, not verified against current vendor pricing this session.

• ?No trial of BPC-157 and KPV together exists in any species at any dose.
• ?No human efficacy trial of either component exists for any gastrointestinal indication. The entire evidence base is rodent.
• ?No human pharmacokinetic data exists for KPV by any route. The under-one-hour clearance figure is inference from its size and lack of modification, not measurement.
• ?No oral bioavailability figure exists for BPC-157. Its gastric acid stability is the basis for oral dosing, but stability is not the same as absorption, and the He et al study reported intramuscular rather than oral bioavailability.
• ?Whether PepT1-mediated KPV uptake demonstrated in mouse colitis models occurs to a comparable degree in human inflamed colon is unverified, though PepT1 upregulation in human intestinal inflammation is described.
• ?Whether delayed-release coatings on commercial capsule products actually deliver intact peptide to the colon is a formulation claim I could not verify for any specific product.
• ?No verified binding affinity figures were resolved for KPV at PepT1 or for any BPC-157 interaction, so those fields are left empty.
• ?Molecular weights for both components are omitted deliberately - neither was verified this session.
• ?The calprotectin threshold given is standard gastroenterology practice, not a finding specific to this blend, and no study has measured calprotectin on either component in humans.
• ?The four-to-eight-week cycle convention is precautionary reasoning from the absence of long-term human safety data plus BPC-157's pro-angiogenic mechanism, not an evidence-based limit.
• ?The pro-angiogenic colorectal cancer concern is mechanistic. No case data links BPC-157 to tumour progression in humans, and equally no study has looked.
• ?Whether BPC-157 is present as the acetate or arginate salt in a given product is frequently unstated and affects solution stability.
• ?Cost ranges are general market observation and were not verified against current vendor pricing this session.
• ?Component sequences in the modifications array are established chemistry but were not independently resolved this session, hence verified false.

• PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D, Gastroenterology, 2008 · PMID 18061177

  The paper that justifies this product's existence and its oral route. Nanomolar KPV inhibits NF-kappaB, uptake is PepT1-mediated in epithelial and immune cells, oral KPV reduces colitis severity in mice, and the effect does not require melanocortin receptors. If you read one citation on this page, read this one.

• Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T, Inflammatory Bowel Diseases, 2008 · PMID 18092346

  Independent murine IBD confirmation from a different group in the same year. Two independent groups reaching compatible conclusions is the strongest thing this blend has, and it is still mice.

• Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D, Molecular Therapy, 2017 · PMID 28143741

  Shows where serious KPV development went - colon-targeted oral delivery. This is the strongest argument for choosing a delayed-release oral capsule of this blend over the injectable version.

• Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, Zhang W, Wang S, Wang Z, Hao Q, Zhang C, Gao Y, Gu J, Zhang Y, Li W, Li M, Frontiers in Pharmacology, 2022 · PMID 36588717

  The only real ADME study on BPC-157: half-life under 30 minutes, linear kinetics, intramuscular bioavailability 14 to 19 percent in rats and 45 to 51 percent in dogs, urine and bile elimination. The short half-life is the argument for splitting the daily dose.

• Stable Gastric Pentadecapeptide BPC 157 and Wound Healing Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, Vuletic LB, Sikiric P, et al, Frontiers in Pharmacology, 2021 · PMID 34267654

  The BPC-157 mechanism review including the gastrointestinal cytoprotection work - NSAID and alcohol lesion models, fistula and anastomotic healing - which is the oldest and largest part of its evidence base and the most relevant to this blend.

• Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy Sikiric P, Drmic D, Sever M, Klicek R, Blagaic AB, Tvrdeic A, Seiwerth S, et al, Current Pharmaceutical Design, 2020 · PMID 32329684

  The fistula healing literature specifically, which is what gets cited when this blend is recommended for perianal or enterocutaneous fistulas in Crohn's disease. Rodent models throughout, and worth reading before accepting that recommendation.

• Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM, Current Reviews in Musculoskeletal Medicine, 2025 · PMID 40789979

  Independent recent review of BPC-157 from outside the originating research group. Musculoskeletal-focused rather than gut-focused, but it is the best available calibration of how far the BPC-157 evidence actually reaches.

• alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs Luger TA, Brzoska T, Annals of the Rheumatic Diseases, 2007 · PMID 17934097

  Background on the alpha-MSH fragment class, useful for the skin and immune claims that come with the KPV component.